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Abstract
Silybin, is one imminent therapeutic for drug induced hepatotoxicity, human prostrate adenocarcinoma and other
degenerative organ diseases. Recent evidences suggest that silybin influences gluconeogenesis pathways favorably and is
beneficial in the treatment of type 1 and type 2 diabetes. The compound however is constrained due to solubility (0.4 mg/
mL) and bioavailabilty limitations. Appropriate nanoparticle design for silybin in biocompatible polymers was thus proposed
as a probable solution for therapeutic inadequacy. New surface engineered biopolymeric nanoparticles with high silybin
encapsulation efficiency of 92.11% and zeta potential of +21 mV were designed. Both the pure compound and the
nanoparticles were evaluated in vivo for the first time in experimental diabetic conditions. Animal health recovered
substantially and the blood glucose levels came down to near normal values after 28 days treatment schedule with the
engineered nanoparticles. Restoration from hyperglycemic damage condition was traced to serum insulin regeneration.
Serum insulin recovered from the streptozotocin induced pancreatic damage levels of 0.1760.01 mg/lit to 0.5760.11 mg/lit
after nanoparticle treatment. Significant reduction in glycated hemoglobin level, and restoration of liver glycogen content
were some of the other interesting observations. Engineered silybin nanoparticle assisted recovery in diabetic conditions
was reasoned due to improved silybin dissolution, passive transport in nanoscale, and restoration of antioxidant status.
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Introduction
Diabetes mellitus is a pathological condition which results in
severe metabolic imbalances and is characterized by high blood
glucose level, low blood insulin level or insensitivity of target
organs to insulin. Prevalence of diabetes is growing globally at an
alarming rate. The World Health Organization (WHO) projects
that the disease will be the 7th leading cause of death by the year
2030 [1]. Nearly 80% of diabetes deaths are currently reported
from the highly populated countries including India, China and
Thailand [2,3]. Most of the synthetic antidiabetic drugs like
sulphonylureas, biguanides, a-glucosidase inhibitors and thiazoli-
denes are associated with unwanted side effects and may cause
significant diminution in glycemic responses [4].
Alternatively, different bioflavonoids from plant sources are
regularly reported for control of postprandial glucose level.
Quercetin for example, was observed to potentiate insulin release,
enhance calcium uptake and facilitate regeneration of pancreatic
islets. [5,6]. However, flavonols and flavonoids are often associated
with poor aqueous solubility and are easily metabolized in the gut
and liver microsomes by enzyme systems such as catechol-O-
methyltransferase (EC 2.1.1.6), phenol sulfotransferase (EC
2.8.2.1) or the UDP glucuronosyl transferases (EC 2.4.1.17)
[7,8]. Consistent delivery and smart dissolution of flavonoid
candidate compounds are contemporary challenges that are
studied widely to meet some of the precise therapeutic require-
ments. Application of current knowledge in apposite nanoparticle
design appears one likely solution in that direction. Stevioside from
Stevia rebaudiana leaves in Poly lactic acid (PLA) nanoparticles have
been proposed recently as a new tool in control of diabetic
conditions [9].
Silymarin (Sm) is one of the oldest traditional herbal medicines
used to combat different organ disorders. Sm is predominantly
composed of four flavonolignan isomers; silybin, isosilybin,
silychristine and silydianin amongst which, silybin (Sb), is the
key biologically active compound and constitutes 34% by mass of
Sm [10,11]. Hepatoprotective effects of Sb have been demon-
strated repeatedly in humans and the most remarkable use of Sb
was in the treatment of acute mushroom (Amanita phalloides)
poisoning [12]. The compound is lowly toxic and exerts significant
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anti-carcinogenic and anti-inflammatory effects and its biomolec-
ular mechanisms in different disease modifications have also been
established [13,14]. Sb has been very recently proposed to be
beneficial in type 2 diabetes patients and a number of articles
demonstrated decreases in both fasting and mean daily glucose,
triglycerides and total cholesterol levels [15–17]. Aqueous extract
of Silybum marianum rich in Sb exerts potent hypoglycemic and
antihyperglycemic activities in both streptozotocin and alloxan-
induced diabetic rats [18,19]. Antidiabetic effect of Sb is attributed
to inhibition of gluconeogenesis in the liver and decrease of
glucose-6 phosphatase activity [20]. Sm acts as an agent for two
way control against streptozotocin induced up regulation of
cytochrome P 450 3A2 enzyme system and down regulation of
glutathione peroxidase [21]. Liver and pancreas centric effects of
Sb in control of diabetes are generally accepted but appropriate
delivery design has remained a significant constraint in systematic
evaluation and further applications. Sb is a low water soluble and
low permeable biopharmaceutic class IV type compound that
faces stipulated requirements in delivery design. Delivery devel-
opment for Sb is therefore one urgent need to reap benefit in
ailments such as diabetes. Flavonol centric antidiabetic design is
also likely to provide a newer direction in management of one of
the most rapidly progressing degenerative ailments in humankind.
Poly DL-lactide-co-glycolic acid (PLGA) is a safe; US FDA
approved biopolymer for applications in nanopharmaceuticals.
However, the biopolymer undergoes a degree of hydrolysis during
its passage in GI tract [22]. Cationic modifications can enhance in
appropriate pay load delivery. Polycationic modification with
chitosan, a mucoadhesive permeability enhancer has been
successful to that effect. Moreover, nanoparticle engineering with
triblock pluronic biopolymers was earlier demonstrated by us to
help in chitosan embossing and programmed drug dissolution
[23]. Earlier systematic analysis and observations [24] in addition,
incited us to exploit different techniques including nanoparticle
engineering for loading a useful mass of the principle bioactive
component Sb in PLGA based nanoparticles. Acetone is a widely
accepted solvent for preparation of PLGA nanoparticles due to its
miscibility with water in all proportions [25,26]. Spontaneous
diffusion of acetone in water creates an interfacial turbulence
resulting in formation of particles in nanoscale. This principle was
experimented for entrapment of Sb in PLGA. Pluronic F-127 (or
poloxamer 407) was used as stabilizer. Pluronics are a group of
ABA triblock copolymers having poly ethylene glycol (PEG) as
outer block and hydrophobic poly (propylene oxide) (PPO) as
middle block and can help in modifying the fate of synthesized
nanoparticles [27]. Pluronic F-127 has also been approved
recently by the US FDA for application in drug delivery devices.
The new nano-device designed with Sb as a payload was studied in




All solvents and water used were of HPLC grade (E. Merck,
India). Silybin, streptozotocin, PLGA (50:50, MW 40,000–
75,000), chitosan (MW medium), dialysis tubing (MW cut off
12,400), fluorescein isothiocyanate (FITC), pluronic F-127 (MW
12,600) were all purchased from Sigma-Aldrich (St. Louis, MO,
USA). Diagnostic kits for estimating blood glucose, cholesterol,
triglyceride, aspartate aminotransferase (AST), alanine transami-
nase (ALT) and alkaline phosphatase (ALP) were purchased from
Span Diagnostics Limited, India. Enzyme linked immunosorbent
assay (ELISA) rat insulin kit was purchased from DRG Diagnos-
tics, Germany. Glycohemoglobin estimation kit was purchased
from EAGLE Diagnostics, USA. Windows Excel (version 2003;
Redmond, WA), statistical package SPSS/10.0 (SPSS, USA),
Sigmaplot (version 6.0; Zendal Scientific, USA) softwares were
used for data analysis.
Preparation of silybin nanoparticles (CSbnp)
Nanoparticles were prepared following a facile and scalable
solvent diffusion technique. Briefly, 10 mg of Sb and 50 mg of
PLGA were dissolved together in 3 mL of acetone. The organic
phase was then added into a 30 mL of aqueous solution containing
1% w/v pluronic F-127. The addition was made by a syringe
pump at a rate of 15 mL/sec under magnetic stirring. Stirring was
continued for an additional period of 12 h to evaporate off
acetone. Nanoparticles were then recovered by ultracentrifugation
(Hitachi Koki, Japan) at 30,000 rpm for 30 min at 4uC. The
particles were further washed two times with HPLC grade particle
free water to remove unincorporated Sb, unbounded polymer and
the stabilizers.
Final chitosan embossed silybin nanoparticles (CSbnp) were
prepared by polyelectrolyte deposition of chitosan. Briefly, the
nanoparticles prepared as above were dispersed in water and
added drop wise into a 0.1% w/v chitosan solution in 1% v/v
aqueous acetic acid under magnetic stirring for 2 h. CSbnps were
harvested similarly by ultracentrifugation and subsequent two step
washings.
Characterization of Nanoparticles
Particle size, zeta potential and morphology. The parti-
cle size and size distribution of nanoparticles prepared were
measured in Zetasizer Nano ZS (Malvern Instruments, Malvern,
UK) against a 4 mw He–Ne laser beam with 633 nm wavelength
at 25uC and back scattering angle of 173u. Aliquots from
preparation batches were sampled in disposable cuvettes and the
particle size along with polydispersity index (PDI) were recorded
using appropriate parameter inputs. Zeta potential of sample sets
was analyzed in the same instrument following the particle
electrophoretic light scattering. Aliquots were injected in zeta cells
and the zeta potential was determined under an electrical field.
The morphology and shapes of the nanoparticles were
investigated under an atomic force microscope (AFM). Micro-
graphs of CSbnp suspensions were obtained in tapping mode using
RTESP tips having resonance frequency of 150–300 kHz at a scan
speed of 1.2 Hz in a Pico plus 5500 ILM (Agilent, USA) atomic
force microscope. Images were captured and analysed using
Picoview 1.10.4 software.
Morphology and size of the nanoparticles were also evaluated
by negative staining method in FEI Tecnai TM Transmission
Electron Microscope (Netherland). For TEM measurements,
10 mL of CSbnp suspension in water was carefully placed on
300 mesh formvar-coated copper TEM grid (Ted Pella Inc., CA,
USA) followed by staining with 2% w/v of uranyl acetate solution
for 5 min. The excess solution on the grid was removed using a
piece of fine filter paper and the samples were allowed to air dry
for 10 h. Images were captured at 80 KV.
FTIR spectroscopy
FTIR studies were carried out in a FT/IR-670 plus (Jasco,
Tokyo, Japan) to detect interaction of each component before and
after nanoparticulation. Sb, chitosan, PLGA, pluronic and the
nanoparticles were pelletized individually with IR grade KBr in
the ratio of 1:100 in a hydraulic press at a pressure of 150 bar for
30 sec. The pellets were scanned over a range of 4000 to
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400 cm21 at a resolution of 4 cm21 and the data stacked in Biorad
KnowItAll software for analysis and overlap regions.
Evaluation for silybin encapsulation efficiency
Encapsulation efficiency of CSbnp was determined from the
amount of Sb originally taken and the amount remaining in the
supernatant after harvesting the nanoparticles following a validat-
ed HPLC method [24]. Sample solutions from the preparation
batch acetone solutions or the nanoparticle supernatants were
filtered through a 0.22 mm membrane, diluted in HPLC mobile
phase and injected into a HPLC system (Waters dual pump HPLC
model 515, New Castle, DE). Sb was analyzed at 288 nm in a
Figure 1. Shape and surface morphological of CSbnp. Atomic force microscopy of CSbnp (A) and transmission electron microscopy of CSbnp
(B).
doi:10.1371/journal.pone.0101818.g001
Figure 2. FTIR scans for silybin, PLGA, chitosan, pluoronic and CSbnp. A) FTIR scan over the mid IR region (cm21), B) comparison zone
upfield, C) comparison zone down field. [Colour codes silybin (red); PLGA (brown); chitosan (blue); pluoronic (sea green); CSbnp (green)].
doi:10.1371/journal.pone.0101818.g002
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reverse phase C18 column (Supelco, Bellefonte, PA, USA)
(2564.6 mm, 5 mm size). Mobile phase used was 85% phosphoric
acid: methanol : water (0.5:46:64 v/v/v) at a flow rate of 1 mL/
min. Peak area (y) vs concentration (x) graph was first developed
from different known concentrations of Sb and was used routinely.
Chitosan coating estimation
Chitosan quintessence on CSbnp was measured using a
chitosan electrostatic interaction reaction with alizarin red dye
[28]. A standard graph from chitosan and alizarin reaction
extinction recorded at 571 nm was used to estimate chitosan mass
content both in the primary stock solution and in CSbnp
preparation supernatant after centrifugation. The difference in
mass was considered for estimation of chitosan coating. Experi-
ments were run in triplicate in each case and the data recorded in
percentage entrapment from three separate batch preparations.
Silybin release kinetics and modeling
For drug release studies, CSbnp equivalent to 9 mg of Sb
payload dispersed in 5 mL of phosphate buffer (100 mM, pH 7.4)
was transferred into dialysis bags (MW cut off 12.4 KD) and was
placed in glass vials containing 100 mL of buffer in a shaker bath
maintained at 70 rpm, 37uC. At predetermined time intervals,
10 mL of phosphate buffer solution was removed for analysis and
the release medium replaced with fresh buffer in order to maintain
the sink conditions. The Sb mass released at definite time intervals
was estimated in HPLC from the release medium aliquots [24].
Standard curve plot was used for analysis with necessary
corrections for the dilution factors. The release data was fitted in
Korsemeyer-Peppas model and the n and K values were
calculated using sigma plot 6.0 software in order to understand
the nanoparticle release mechanisms.
CSbnp in streptozotocin (STZ) induced diabetic rats
Ethics Statements. Male Wistar rats weighing 170–200 g
were procured from Central Research Institute, (Kolkata, India).
Animals were acclimatized under standard laboratory conditions
of relative humidity 50610%, temperature 2262uC and 12/12
light dark cycle for 2 weeks prior to the start of experiments.
Access to water was ad libitum and standard pellet food (Hindustan
Uniliver, India) supply was provided twice a day till the start of the
experiments. This study was carried out in strict accordance with
the recommendations in the Guide for the Committee for the
Purpose of Control and Supervision of Experiments on Animals
(CPCSEA), Government of India. The protocol was approved by
the institutional animal ethical committee (IAEC) of University of
Figure 3. In-vitro dissolution studies for CSbnp. Results expressed as mean 6 SD (n = 4). In vitro release of Sb from CSbnp was plotted as
average percentage cumulative release over time.
doi:10.1371/journal.pone.0101818.g003
Figure 4. Blood glucose level in different groups during the 4
weeks experimental period. C – control group, D – diabetic group,
SbT – Sb treated group, CSbnpT – CSbnp treated group. Results were
expressed as mean 6 SD (n = 6). *P,0.001 highly significant difference
compared with diabetic group. ¥P,0.001 highly significant difference
when compared between SbT and CSbnpT.
doi:10.1371/journal.pone.0101818.g004
Figure 5. Intraperitoneal glucose tolerance test in different
groups of rats. C – control group, D – diabetic group, SbT – Sb treated
group, CSbnpT – CSbnp treated group. Data represented as mean6 SD
(n = 6).
doi:10.1371/journal.pone.0101818.g005
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Calcutta (Approval no. 506/01/a/CPCSEA/CUTech03).
Induction of diabetes
Before the induction of diabetes, the animals were weighed and
basal blood glucose level was measured. Glucose tolerance test
(GTT) was carried out at the start of the experiment to assess the
glucose homeostasis in normal conditions and to detect the stages
of pre-diabetic condition if any. Animals were fasted for a period
of eight hours prior to analysis with water ad libitum. Each test
animal was then challenged intraperitoneally with a freshly
prepared aqueous D-glucose solution (2.0 g/kg). Blood glucose
level was measured in the blood samples taken from the tail vein
after 30, 60, 90 and 120 min of glucose injection and also initially
at the 0th time. Individual data was recorded and animals with
normal glucose homeostasis were considered for further experi-
ments.
Diabetes was induced in overnight fasted groups by single
intraperitoneal injection of STZ at a dose of 50 mg/kg body
weight in freshly prepared citrate buffer (0.1 M pH 4.0) [21].
These animals were fed with standard pellet food and a 5%
glucose solution ad libitum, for 72 h. Afterwards the glucose
solution was replaced with water. The control animals received the
vehicle alone. The diabetic state was assessed by measuring fasting
glucose level of blood taken from the tail vein. Rats with a blood
glucose level above 250 mg/dL were considered as diabetic and
were used in further experiments.
Study design
Animals were divided into four groups of 6 animals each with
the following treatment schedule.
Group C – Normal control received normal saline only.
Group D – STZ only induced rats served as diabetic control.
Group SbT – STZ induced diabetic rats treated ip with Sb
50 mg/kg b.w for 28 days (diabetic and Sb treated).
Group CSbnpT – STZ induced diabetic rats treated ip with
CSbnp equivalent to 50 mg/kg Sb payload for 28 days (diabetic
and CSbnp treated).
Blood glucose estimation
Fasting blood glucose (FBG) concentration was monitored in
blood samples extracted from the tail of each animal every week
during the entire experimental period and at the end of the
treatment in the morning, using a glucometer (Dr. Morepen Gluco
One Blood glucose monitoring system BG 03) with maximum
measuring capacity of 600 mg/dL.
Intraperitoneal glucose tolerance test (IPGTT)
IPGTT test was performed twenty four hours after the last dose
of treatment following the procedure as discussed earlier for GTT.
Briefly a sterile 20% glucose was injected (ip) at a dose of 2.0 g/kg
body weight. Blood was collected from the tail vein to estimate
glucose level before (0th time) and 30, 60, 90 and 120 min after
glucose injection by glucometer.
Euthanization and tissue preparations
After completion of IPGTT studies, animals were fasted
overnight and FBG levels were checked. Body weight of each
animal was recorded before and every week till the end of the 30
days experimental period. Blood samples (1.5–2.0 ml) were
collected by cardiac puncture under light anesthesia. Samples
were collected in marked vials added with or without anticoag-
ulant for plasma and serum analysis and were stored at 220uC
until further studies. The animals were finally euthanized by using
CO2 gas and the tissue samples were collected for analysis. The
liver and pancreas specimens were immediately removed and
rinsed with chilled normal saline and dissected in two parts. The
first part following a snap freeze in liquid nitrogen was stored at 2
80uC for further molecular and biochemical analyses and the
second half was kept in 10% formalin for histopathological
examinations.
Biochemical assays
Serum analysis. The serum prepared from the blood
samples was subjected to estimation of cholesterol and triglyceride
levels by using estimation kits (Span Diagnostics Limited, India)
following the manufacturer’s instructions.
Figure 6. Effect of Sb and CSbnp treatment on body weight in
rats. C – control group, D – diabetic group, SbT – Sb treated group,
CSbnpT – CSbnp treated group. Results were expressed as mean 6 SD
(n = 6). ?P,1.0 no significant difference compared with initial body
weight. $P,0.05 significant difference when compared with initial body.
doi:10.1371/journal.pone.0101818.g006
Table 1. Effect of Sb and CSbnp on serum insulin, cholesterol and triglyceride levels in diabetic rats.
Animal group Insulin (mg/lit) Cholesterol (mg/dl) Triglyceride (mg/dl)
Control (C) 0.6060.06 77.666.54 5568.02
Diabetic (D) 0.1760.01 152.669.73 167.67614.13
D + Sb (SbT) 0.2960.06? 108.2610.12* 127.5620.17Q
D + CSbnp (CSbnpT) 0.5760.11*,¥ 8066.13*,¥ 92.67610.09*,¥
Results expressed as mean 6 SD (n = 6).
?P,1.0 no significant difference compared with D group.
*P,0.001 highly significant difference compared with D group.
¥P,0.001 highly significant difference compared amongst Sb and CSbnp treated group.
QP,0.01 significant difference compared with D group.
doi:10.1371/journal.pone.0101818.t001
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Serum insulin levels were measured using rat insulin ELISA kit
[29]. Metabolic enzyme activities of aspartate aminotransferase
(AST), alanine transaminase (ALT) and alkaline phosphatase
(ALP) were estimated using commercially available kits (Span
Diagnostics Limited, India).
Estimation of total protein
Total protein was estimated in serum and in liver tissue using
bovine serum albumin (BSA) as a standard following the method
of Lowry et al. [30].
Serum fructosamine
Serum fructosamine (Amadori product) was determined by
nitroblue tetrazolium (NBT) reduction assay according to the
method of Johnson et al. [31]. Briefly, 1 mL of NBT reagent
(0.5 mM NBT in 0.2 M sodium carbonate buffer pH 10.4) was
added to serum (100 mL) and the mixture was incubated at 37uC
for 1 h. The absorbance was measured at 530 nm against a
reagent blank. The concentration of fructosamine was calculated
compared to 1-deoxy-1-morpholino-fructose (1-DMF) as the
standard [32].
Estimation of oxidative stress markers and the
antioxidant system
Determination of serum lipid peroxidation. Serum mal-
ondialdehyde (MDA) level as a measure of lipid peroxidation was
assayed in the form of thiobarbituric acid (TBA) reactive substance
following the method of Yagi [33]. Briefly, 400 mL of serum was
diluted with 100 ml of distilled water. Trichloroacetic acid solution
(TCA, 2.5 mL, 1.22 M) was added to the serum sample and the
mixture was kept at room temperature for 15 min. 1.5 mL of
0.76% TBA containing 0.05 (M) NaOH was then added to the
mixture and incubated in a boiling water bath for 30 min. The
reaction mixture was cooled and 4 mL n-butanol was added into
it. The resultant chromophore was extracted from the butanol
phase. The generation of MDA was measured from the
fluorescence emission intensity of the resultant chromogen at
553 nm by excitation at 515 nm. The results were expressed in
fluorescence unit/mg of protein.
Estimation of SOD, Catalase and GSH in liver tissue
Liver tissues were minced and homogenized (tissue homogeniz-
er, TH 02, Omni International, Kennesaw, GA) in 10 mM
potassium phosphate buffer containing 0.1 mM EDTA, pH 7.4, at
a proportion of 1:9 (w/v). The homogenate was centrifuged at
6000 g for 10 min at 4uC. The resultant supernatant was used for
the determination of catalase and SOD activities and estimation of
glutathione (GSH) content.
SOD activity was measured according to the method of
Marklund and Marklund [34]. In this test, the degree of inhibition
of pyrogallol auto-oxidation by the supernatant of the tissue
homogenate (100 mL) was measured. One unit of enzyme activity
was defined as the amount of enzyme necessary for inhibiting the
reaction by 50%. The enzyme activity was expressed as units per
gram of tissue.
The catalase assay was carried out as described by Aebi [35].
Briefly, 50 mL of the supernatant was taken with 2950 mL of
phosphate buffer (10 mM, pH 7.4). Hydrogen peroxide (80 mL,
10 mM) was further added to initiate the reaction. A blank was
prepared with 3000 mL of the phosphate buffer and 80 mL of
H2O2 without tissue homogenates. The decrease in optical density
due to decomposition of H2O2 was measured at the end of 1 min
compared to the blank at 240 nm. Enzyme activity was defined in
terms of units of catalase required to decompose 1 mM of H2O2
per minute at 25uC. The specific activity was expressed in terms of
units/mg of tissue.
Tissue content of GSH was estimated following Ellman’s
method with some modifications [36]. Briefly, 200 mL of sodium
EDTA solution (20 mM) was added to 200 mL of the supernatant
and was kept for 10 min at 4uC. 400 mL of 5% TCA was added
and the mixture was left for 5 min at room temperature. After
centrifugation, 500 mL of the supernatant was collected and
500 mL of Tris buffer (200 mM, pH 8.4) and 50 mL 5,59-dithiobis-
(2-nitrobenzoic acid) (DTNB, 100 mM) were added. Optical
density was monitored after 3 min at 412 nm against deionized
water. A blank reaction run was also run by mixing 500 mL Tris
buffer and 50 mL DTNB and the average of absorbance at the
beginning and at the end of the reaction was recorded. The blank
Table 2. Effect of Sb and CSbnp over liver metabolic enzymes in diabetic rats.
Animal group AST (IU/L) ALT (IU/L) ALP (IU/L)
Control (C) 9469.11 47.3363.24 82.3366.38
Diabetic (D) 168611.57 90.3367.18 213.66617.86
D + Sb (SbT) 132.66612.87Q 72.1666.48* 188.33613.54*
D + CSbnp (CSbnpT) 109.1669.57*,¥ 5866.65*,¥ 129.83611.5*,¥
Results expressed as mean 6 SD (n = 6).
QP,0.01 significant difference compared with D group.
*P,0.001 highly significant difference compared with D group.
¥P,0.001 highly significant difference compared amongst Sb and CSbnp treated group.
doi:10.1371/journal.pone.0101818.t002
Figure 7. Effect of Sb and CSbnp treatment on serum MDA
level in rats. C- control group, D – diabetic group, SbT – Sb treated
group, CSbnpT – CSbnp treated group. Results were expressed as mean
6 SD (n = 6). *P,0.001 highly significant difference compared with D
group. ¥P,0.001 highly significant difference compared amongst Sb
and CSbnp treated group.
doi:10.1371/journal.pone.0101818.g007
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reading was subtracted from each sample readings and the results
were expressed as mM/mg of tissue.
Determination of the glycogen content in liver
The glycogen content was estimated according to the method of
Murat and Serfaty [37]. Briefly, liver tissues were homogenized in
ice-cold citrate buffer (0.1 M, pH 4.2) at a ratio 1:9 (w/v), followed
by centrifugation at 10,600 g for 30 min at 4uC. The free glucose
content in the supernatant was then measured by GOD/POD
method using the assay kit (Span Diagnostics Limited, India) [38].
Amyloglucosidase (2 mg, Sigma, USA) was added to the
homogenate (500 mL) and was further incubated for 4 h at
37uC. The total glucose content after incubation was then
measured similarly. The glycogen content in the liver was
calculated as the difference between total and free glucose.
Estimation of glycohemoglobin (HbA1c) content
HbA1c in blood was estimated by the ion-exchange resin
method [39,40]. Whole blood (100 ml) was mixed with lysing
reagent and the hemolysate was loaded to a cation exchange
column (EAGLE Diagnostics, USA). Unmodified hemoglobins
were retained by the resin, and HbA1c (fast fraction) was eluted.
The percentage of HbA1c was determined by measuring the ratio
of absorbance of the HbA1c fraction and the total hemoglobin
fraction in the hemolysate at 415 nm.
Advanced glycated end product (AGE)
RBC hemolysates were prepared after washing the cells with
normal saline followed by hypotonic lysis in deionized water. Total
hemoglobin (Hb) was isolated and purified by Sephadex G-100
column chromatography, pre-equilibrated with 50 mM potassium
phosphate buffer, pH 7.4. The concentration of Hb was measured
from Soret absorbance with the extinction coefficient as
125 mM21cm21 at 415 nm and the results were calculated on
monomer basis [41]. AGEs in Hb were estimated spectro-
fluorimetrically from the fluorescence emission at 440 nm with
excitation at 370 nm [42].
Histopathological analysis
Tissues were fixed in 10% v/v formalin and dehydrated in a
series of ethanol solutions (70, 80, 90, 100% v/v). The tissue
samples were processed by using paraffin block techniques in wax.
The samples were then sectioned (>5 m) stained with hematox-
ylin-eosin and mounted with neutral DPX medium. Photograph of
stained sections were captured with a camera attached to a light
microscope (B1 series, Motic, Xiamen, China).
Statistical analysis
Data were expressed as mean 6 SD. Gathered data were
assessed using one-way analysis of variance (ANOVA) with post hoc
pair-wise comparisons between groups using the Bonferroni
method. For all analyses, P,0.05 was considered significant and
P,0.001 highly significant. Statistical analysis was performed
using the statistical package SPSS/10.0 (SPSS, USA).
Results and Discussion
Nanoparticles and characterizations
Nanoparticulation of biopharmaceutic class IV type compounds
is one strategy that is helpful in dissolution improvements, specific
administration and facilitated bioactivity [43]. PLGA nanocarriers
with Sb payload were prepared by solvent diffusion of acetone in
water environment. Diffusion of solvent in water phase resulted in
rapid particle formation. As the solvent rapidly diffuses into the
water phase, an interfacial turbulence results which, can cause
deposition of polymer at the transient acetone/water interface.
Some advantages of this technique are mild preparative condi-
tions, avoidance of high stress force and an apparent ease in future
scale ups. US FDA approved tri block polymer pluronic F-127 (or
poloxamer 407) was used as a stabilizer in place of common agent
PVA. In contrast to PVA, pluronics interact with both hydropho-
bic and hydrophilic domain and provide a brush-like coat which
could provide stability to nanoparticles during preparation and in
the physiological environment [44]. Chitosan association on
nanoparticle surface was one likely reason for a sustained release
Table 3. Effect of Sb and CSbnp over antioxidant status of liver in diabetic rats.
Animal groups SOD (U/gm of tissue) Catalase (mU/mg of tissue) GSH (mM/mg of tissue)
Control (C) 7.6460.98 146.568.90 4.0260.31
Diabetic (D) 3.4260.64 88.568.76 2.5460.21
D + Sb (SbT) 5.6460.78? 113.83611.34Q 2.9360.12J
D + CSbnp (CSbnpT) 6.8460.32Q,¥ 134.1668.74*,a 3.5460.16*,¥
Results expressed as mean 6 SD (n = 6).
?P,1.0 no significant difference compared with D group.
QP,0.01 significant difference compared with D group.
*P,0.001 highly significant difference compared with D group.
JP,1.2 no significant difference compared with D group.
¥P,0.001 highly significant difference compared amongst Sb and CSbnp treated group.
aP,0.05 significant difference compared amongst Sb and CSbnp treated group.
doi:10.1371/journal.pone.0101818.t003
Figure 8. Effect of Sb and CSbnp on liver glycogen content. C-
control group, D – diabetic group, SbT – Sb treated group, CSbnpT –
CSbnp treated group. Results were expressed as mean6 SD (n = 6). $P,
0.05 significant difference compared with D group.
doi:10.1371/journal.pone.0101818.g008
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and controlled drug permeability. Average hydrodynamic diam-
eter of the prepared CSbnp was recorded in DLS as 229.7 nm and
the PDI was 0.124. This indicated particle uniformity in the
preparation system.
Presence of molecular layer of polycationic chitosan on PLGA
was evident from a positive zeta potential value of +21 mV. Silybin
entrapment percentage in CSbnp was determined routinely in a
reverse phase HPLC [24] set up and was recorded as high as
92.11%. AFM analysis of CSbnp revealed smooth surface
topography for particles with mostly spherical geometry
(Figure 1). A degree of coalescence in the AFM scans over time
was also noticed in the observation scales. Transmission electron
microscopy showed discrete nanoparticles nearly spherical in
shape having mean particle diameter of 184.6 nm. The diameter
of the particles observed in the TEM was relatively smaller than
the hydrodynamic diameters observed in the DLS method. Similar
size differences were reported by other researchers [45].
In FTIR, the characteristic Sb benzopyran ring vibration was
recorded at 1084 cm21 [46] alongside the flavonolignan ketone
response at 1634 cm21. The C-H deformation was observed at
821 cm21 and the aromatic ring stretching vibrations were at
1508 cm21 (Figure 2). In case of PLGA, the ester -CO response
was distinct at 1757 cm21 while the biopolymer C-H stretching
was recorded at 2997 cm21. Chitosan when scanned in FTIR
responded, at 1656 cm21 and 1591 cm21 due to amide I and
amide II vibrations. In CSbnp, a strong shift due to electrostatic
interaction of amide I appeared to a lower wave number at
1624 cm21, and a feeble response for chitosan -NH was clear.
Non-covalent conjugations were clearly attributed in case of
CSbnp. Observations of amide I shift and the loss of amide II
response due to strong electrostatic interactions between biopoly-
meric -COO2 and the chitosan NH3
+ groups were thus confirmed
[47].
Chitosan estimation
Chitosan mass in final CSbnp was analyzed on the basis of free
chitosan left in the supernatant initially and after particle
separations. A standard curve y = 0.0037x+0.1649, R2 = 0.9863,
originally developed from the concentration (x) vs. absorbance (y)
due to chitosan alizarin reaction in acidic pH environment (pH 5)
was used to quantify the chitosan mass. The percentage chitosan
coating efficiency on weight basis was recorded as 77.8163.23.
In vitro release
Time-dependent cumulative Sb percentage release from CSbnp
was studied and almost 85% of the initial Sb mass load was
accountable during the study period (Figure 3). Release pattern
was biphasic, initial fast release lasted up to 8 h followed by a
sustained and steady release phase. Chitosan forms an entangled
network layer on the particle surface which restricts the entry of
water as well as prevents diffusion of drug molecules from
nanoparticle surface to the surrounding medium that effectively
controlled the release patterns [48]. Besides, the solubility of
chitosan is pH dependent and at pH 7.4 it reduces the rate of
diffusion of water in CSbnp. This initial fast release phase was
followed by a very sustained and steady release for 31% of Sb mass
payload over a period of 120 h. Drug release from particulate
delivery devices is generally associated with intersects of multiple
phenomenon including drug diffusion, polymer swelling, polymer
erosion and degradation. The Peppas release exponent ‘n’ value of
0.45 for CSbnp indicated a potential overlapping of multiple
incidents over the observation period [49].
CSbnp in streptozotocin (STZ) induced diabetic rat
Effect of silybin and CSbnp on STZ induced
hyperglycemia and glucose tolerance. Fasting blood glucose
was monitored in different groups of rats at different time intervals
and is presented in Figure 4. STZ treatment caused a rise in blood
glucose (P,0.001) in comparison to that in the control group.
Both Sb and CSbnp treatment resulted in reduction of blood
glucose level in comparison to the diabetic group D. However,
CSbnp treatment exhibited a highly significant (P,0.001) down
regulation of blood glucose levels compared to only Sb treated
group by the end of the third week of the study period.
Glucose tolerance test is a more sensitive tool for recording early
abnormalities in glucose regulation than fasting blood glucose
measurement. Pancreatic dysfunction leads to defective utilization
of glucose by the tissues that result in impaired glucose tolerance.
Diabetic rats exhibited glucose intolerant behavior in comparison
with the control (Figure 5). Rise of glucose level in diabetic rats was
unabated even after two hours of glucose load due to impaired
glucose homeostasis. Blood glucose level of diabetic rats when
treated with CSbnp returned to near normal levels in 120 min
Table 4. Effect of Sb and CSbnp on glycohemoglobin (HbA1c) and fructosamine levels in diabetic rats.
Animal group Serum fructosamine (mmol/mg of protein) % of HbA1c
Control (C) 0.5960.12 1.7960.37
Diabetic (D) 2.7260.64 5.8860.58
D + Sb (SbT) 1.1260.45* 4.3360.12*
D + CSbnp (CSbnpT) 0.5660.03* 2.2460.24*,¥
Results expressed as mean 6 SD (n = 6).
*P,0.001 highly significant difference compared with D group.
¥P,0.001 significant difference compared amongst Sb and CSbnp treated group.
doi:10.1371/journal.pone.0101818.t004
Figure 9. Effect of Sb and CSbnp on formation of advanced
glycated end product (AGE). C- control group, D – diabetic group,
SbT – Sb treated group, CSbnpT – CSbnp treated group.
doi:10.1371/journal.pone.0101818.g009
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after glucose injection. No significant difference was observed
between glucose tolerance curves of CSbnpT group and the
control group at the end of fourth week of treatment. Sb treated
group (SbT) also exhibited a reversal effect but the blood glucose
still remained higher than the normal level.
Effect of Sb and CSbnp on body weight
The body weight recordings of different treatment groups
before (0th day) and after the experimental period are presented in
Figure 6. Diabetic group of rats showed significant reduction in
body weight (P,0.05) when compared with initial body weight.
There was a significant gain in body weight in the diabetic rats
treated with CSbnp (P,0.05). However there was no significant
gain in body weight (P,1) of diabetic rats treated with Sb. The
relative gain in body weight in CSbnp treated group compared to
diabetic group revealed a steady recovery of animals from the
prior diabetic conditions.
Effect of Sb and CSbnp on serum insulin, cholesterol and
triglyceride levels in diabetic rats
Induction of diabetes resulted in highly significant reduction in
serum insulin level compared to that of control group (P,0.001)
(Table 1). The level improved upon treatment with Sb, but the
improvement was more pronounced when the group was treated
Figure 10. Histopathology examination of pancreas sections. (A) Normal Pancreas, (B) Diabetic Pancreas, (C) Sb treated pancreas, (C) CSbnp
treated pancreas (Magnification 1006). Representative micrographs are shown.
doi:10.1371/journal.pone.0101818.g010
Figure 11. Histopathology examination of liver sections. (A) normal liver, (B) diabetic liver, (C) Sb treated liver (D) CSbnp treated liver
(Magnification 1006). Representative micrographs are shown.
doi:10.1371/journal.pone.0101818.g011
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with CSbnp. Administration of Sb produced moderate restoration
of insulin level which was statistically insignificant in comparison
to that of group D. However in case of CSbnpT group a marked
improvement in insulin level (P,0.001) was observed. CSbnp
treatment in diabetic rats may have assisted in insulin regeneration
and the effect was also statistically highly significant (P,0.001)
when compared to that of SbT animals.
Both Sb and CSbnp treatment have significantly (P,0.001)
reduced serum cholesterol levels as compared to that of the
diabetic control group D. CSbnp reduces triglyceride level
significantly (44.7%, P,0.001) in comparison to Sb (23.9%, P,
0.01). Both serum cholesterol and triglyceride levels were
significantly decreased in CSbnpT rats when compared to that
in the diabetic group D indicating recovery. However, CSbnpT
treated rats attained much lower values of blood cholesterol and
triglyceride levels than that of SbT rats and the differences were of
comparative statistical significance (P,0.001).
The increase in serum glucose and decrease in insulin of
diabetic rats indicated the death of the pancreatic beta cells.
However increase in serum insulin levels in SbT and CSbnpT
groups indicated the probability of pancreatic b -cell regeneration
in these groups. STZ-induced diabetes mellitus causes overpro-
duction and decreased utilization of glucose by the tissues which
results in disturbance of carbohydrate and fat metabolism and are
characterized by hyperglycemia, hypertriglyceridemia, and hyper-
cholesterolemia. Previous studies suggested that Sb in higher
dosage reduced glucagon and induced stimulation of both
gluconeogenesis and glycogenolysis resulting in down regulation
of glucose 6-phosphate hydrolysis [20,50]. Plasma levels of
triglyceride, cholesterol and lipid are therefore likely decreased
through the recovery of energy substrates, inhibition of lipid
peroxidation, membrane stabilization and hyperglycemic depres-
sion [27].
Liver marker enzyme analysis
Liver enzymes ALT, AST and ALP are responsible for proper
functioning of the liver. Hyperglycemia induced hepatocellular
damages lead to excessive leakage of these enzymes into the blood
stream. A rise in AST and ALT concentrations in the serum
indicated hepatocellular damages. ALP is one marker of biliary
function and cholestasis. The increased levels of these enzymes in
the diabetic rats were due to leakage from the liver cytosol as a
result of hepatic tissue damages. STZ induced hyperglycemia
established liver damage as evidenced by the elevated level of
serum ALT, AST and ALP enzymes. Treatment with Sb and
CSbnp helped in lowering of AST, ALT and ALP levels
significantly when compared with that in group D (Table 2).
Diabetic animals treated with Sb and CSbnp however showed
differential activity on reduction of liver marker enzymes. The
decreased AST, ALT and ALP levels of CSbnp treated group were
statistically highly significant compared to that of only Sb treated
group SbT (P,0.001). The significant reversal of AST, ALT and
ALP levels in CSbnpT group indicated noticeable recovery due to
CSbnp [27] treatment.
Effect of Sb and Csbnp on oxidative stress markers and
antioxidant system in diabetic rats
Serum MDA estimation. Oxidative stress in animals was
measured by markers like secondary products of lipid peroxidation
such as thiobarbituric acid reactive species (TBARS). Free radicals
like CH3
+ possess a very short half-life but affect bioactive
molecular mechanisms specifically in diabetic conditions. Serum
MDA level was measured from TBARS formation in different
groups of rat following the method of Yagi [33]. Rise in MDA
level was highly significant (P,0.001) in diabetic group with
respect to that of the control group. Protective effects of Sb and
CSbnp were evident from the significantly reduced levels of MDA
in the respective treated groups. However decrease in MDA level
of CSbnpT group was statistically significant when compared to
that of only Sb treated group (P,0.001, Figure 7).
Evaluation of antioxidant status
Oxidative stress and in particular reactive oxygen species (ROS)
play an important role in induction of diabetes and its associated
complications. An imbalance between reactive oxygen species
(ROS) generation and the reduced activity of antioxidant defenses
may lead to oxidative stress in diabetic condition [21]. Antioxi-
dants could be preventive or protective in similar conditions and
are precious in the treatment of diabetes.
Oxidative stress negatively affects the activities of catalase and
SOD in the liver tissues and also raises the peroxidation levels
[51]. Total antioxidant status was measured by the amount of
enzymatic (SOD, catalase) and non enzymatic (GSH) markers and
is presented in Table 3.
SOD catalyzes the conversion of the superoxide anion to
hydrogen peroxide and the molecular oxygen species. The
observed decrease in SOD activity in diabetic control rats could
be due to inactivation by H2O2 or by glycosylation of the enzyme
in diabetes [52]. Catalase is a haem containing ubiquitous enzyme
which catalyzes the reduction of H2O2 and protects the tissues
against reactive hydroxyl radicals. SOD and catalase activities
were found to be significantly reduced (P,0.001) in diabetic rats
(group D), as compared to those in control rats (group C). The
observed decrease in SOD and catalase activities in diabetic rats
might be due to inactivation of the enzymes by ROS or by
glycosylation, as reported in diabetic condition [52,53]. Sb treated
group exhibited increased SOD level but was statistically
insignificant while CSbnpT group showed significant increase in
activities of antioxidant enzymes SOD (P,0.01) and catalase (p,
0.001).
GSH is a direct scavenger of free radicals as well as a co-
substrate for peroxide detoxification and also it has a versatile role
in antioxidant defense. In diabetic control groups, the decreased
GSH level may be due to its reduced synthesis or enhanced
degradation by oxidative stress [54]. Restorative effect of Sb and
CSbnp were indicated by the improved antioxidant status.
However, compared to the Sb-treated group, CSbnp-treated rats
demonstrated much closer SOD, catalase and GSH levels to those
of the control group (Table 3).
Silymarin was reported to have protective effect on diabetes
induced oxidative damages in the pancreas, kidney and liver
[19,55,56]. The antioxidant effect of silymarin components is
mainly due to its antiradical and reactive oxygen species
scavenging capacities. Additionally polyphenolic silymarin com-
pounds may play an important role in stabilizing lipid peroxida-
tion due to their intrinsic reducing capacity [57].
Estimation of glycogen content
Excess glucose is converted into glycogen under the influence of
insulin. Glycogen is considered as energy fuel of tissues especially
in the liver and skeletal muscles. Glycogen contents measured in
the liver tissues and are shown in Figure 8. Reduced glycogen level
in group D may be related to insulin deficiency and significant
improvement (P,0.05) of glycogen content in SbT and CSbnpT
groups indicated the effective glucose utilization and storage in
these groups. Maximum rise in liver glycogen content was
however observed in CSbnp treated group that could be reasoned
due to nano size assisted transport enhancement of Sb in liver.
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Estimation of serum fructosamine and HbA1c
Fructosamine is a ketoamine formed when the carbonyl group
of glucose reacts with an amino group of proteins in protein
glycation reaction [58]. The Amadori product or fructosamine is
the first stable product of protein modification by glucose and its
level in serum increases in diabetes [59]. Fructosamine can
undergo oxidative cleavage resulting in the formation of advanced
glycation end product (AGE). A significant rise in serum
fructosamine level was observed in diabetic group in comparison
to that of normal control (P,0.001) as shown in Table 4.
Treatment with Sb and CSbnp caused significant reversal of
fructosamine level with respect to diabetic group (P,0.001).
Persistent hyperglycemia results in glycation of hemoglobin
which leads to the formation of HbA1c, which is also proportional
to blood glucose levels. The average HbA1c level was found to be
significantly higher in group D rats than that of control group C
(P,0.001) indicating poor glycemic control. Diabetic rats treated
with CSbnp showed a considerable reduction of glycation level of
hemoglobin (P,0.001) compared to that of only Sb treated group
indicating better glycemic control by nanoparticle treatment
(Table 4).
Estimation of AGEs
In diabetes, Maillard reaction is common with the formation of
AGEs, which are the root causes of different diabetic complica-
tions. AGEs in hemoglobin samples from different groups were
estimated spectrofluorimetrically. Diabetic group showed in-
creased presence of AGE in comparison to group C under
fluorescence emission scan (Figure 9). Reduced level of AGE in
hemoglobin was observed in case of CSbnpT group over the SbT
group which might be related to directed Sb response against
diabetes.
Histopathological study
Pancreatic sections of group C animals showed compact,
regular, nearly rounded islet cells with well defined nuclei and a
grainy appearance in the cytoplasm. (Figure 10A). No evidence of
central necrosis was observed in normal pancreatic section.
Histopathological analysis of pancreatic tissue slices in group D
animals exhibited shrinkage of islet cells and a reduced number of
islet cells. The peripheral islets are infiltrated with lymphocytes
(Figure 10B).
Pancreatic tissue histoarchitecture of CSbnpT group recorded a
marked improvement in the structural integrity of the islets of
Langerhans when compared to the observations in group D. Islet
histoarchitecture, the number of islet cells and peripheral islet
infiltration of lymphocytes appeared to be considerably improved
(Figure 10C). On the other hand, Sb treated group exhibited
better histoarchitecture of islet cells with partial recovery in
comparison to diabetic group (Figure 10D).
Liver sections of non-diabetic control animals exhibited regular
hepatic architecture, prominent centrilobular vein, sinusoidal
spaces and prominent nucleus (Figure 11A). In contrast, sections
of the diabetic rat liver showed accumulation of fat droplets with
distorted morphology of centrilobular vein, hepatocytes, and
occurrence of sinusoidal dilatation (Figure 11B). Treatment with
engineered nanoparticles stimulated significant revival of hepatic
cytoarchitecture with reduction of fat droplets as well as sinusoidal
abnormality (Figure 11D). The revival effect appeared to be better
compared to that of Sb-administered animals (Figure 11C).
Streptozotocin is a nitrosourea analog which is known to
accumulate selectively in pancreatic beta cells via the low-affinity
glucose transporter-2 (GLUT2) in the plasma membrane [60].
Selective toxicity of this agent causes DNA alkylation, protein
glycosylation and depletion of ATP leading to beta cell damages
[61–63]. Insulin biosynthesis, glucose-induced insulin secretion
and glucose metabolism get affected as a result of impaired beta
cell functions [64,65]. Hyperglycemic conditions in diabetes leads
to free radicals generation and induces oxidative stress by
activating mitochondrial NADPH oxidase [66,67]. Oxidative
stress conditions prevent insulin transport through endothelial
walls and limits delivery of the hormone to the tissues [56].
Sm is reported to be associated with strong antioxidant
properties, regenerative effect on beta cells, stabilizing effect on
cell membrane and enhancement of membrane permeability to
glucose [68–70]. Studies have also demonstrated that Sb could
protect pancreas from cyclosporine A-induced toxicity and effect
potent hypoglycemic effects in both type 1 and type 2 diabetes
mellitus [64,16]. Sb also dose-dependently reduces the glucagon-
induced stimulation of both gluconeogenesis and glycogenolysis
and induces a potent decrease in glucose-6- phosphate hydrolysis
[20,50]. Sb induced stabilization of mitochondrial membrane
potential and inhibition of cytokines production likely aid in
antioxidant efficacy.
The results of the present study showed that administration of
Sb exhibited an overall beneficial effect on streptozotocin induced
diabetes in rats. Biopharmaceutic enhancement of Sb through
nanoparticle engineering was marked by down regulation of blood
glucose within two weeks of treatment. Sb also lowered blood
glucose level but failed to normalize the hyperglycemic condition
in contrast to the animals treated with CSbnp nanoparticles.
CSbnp treatment exhibited normoglycemic conditions rapidly
after three weeks of treatment. Nanoparticulation of Sb favored
size assisted passive transport [71], improved dissolution and
enhanced cellular uptake which resulted in improved efficacy of
CSbnp in diabetic animals. Regulated release of Sb could also be
one reason for decreased gluconeogenesis in CSbnpT group which
was reflected in the higher liver glycogen content in treated
animals. Besides CSbnp induced improved antioxidant defense
has helped to regenerate pancreatic beta cell population conse-
quently affecting in higher insulin blood levels. Engineered
nanoformulations like CSbnp with low toxic therapeutic pay load
thus could be a significant contributor in early management of
diabetes conditions.
Conclusion
Silybin, the principle bio-active component of silymarin was
proposed earlier as an alternative therapy in diabetes. Silybin was
successfully nanoparticulated following facile particle engineering
techniques. The molecular loading was higher at 92.11% and the
release profile in new engineered nanoparticles CSbnp was
sustained. CSbnp contribution in diabetes control was profound
and a remarkable response was recorded in the test animals with
recovery to nearly normal insulin levels and reduced glycated
hemoglobin parameters. Liver concentric effects of CSbnp could
be one reason that facilitated antioxidant defence mechanism and
aided in beta cell regeneration. This affected in increased insulin
availability and a concomitant protection for liver glycogen stores.
Such conditions are also likely due to Sb induced interference in
neoglucogenesis pathways. The designed Sb nanomedicines
therefore provided newer directions in diabetes management.
The nanoparticles are likely to aid further in diabetic control and
serve as an adjunct therapeutic.
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